Home>Topics>Stocks>Illumina

Illumina ILMN

  1. All
  2. Commentary
  3. Headlines
    1. Illumina teams with U.S. government, researchers to sequence Ebola

      Headlines

      Wed, 19 Nov 2014

      CHICAGO, Nov 19 (Reuters) - Gene sequencing equipment maker Illumina has teamed up with the U.S. government and academic researchers at the Broad Institute in Boston to train scientists in West

    2. BRIEF-Biomerieux agrees with Illumina to launch NGS epidemiology solution for service labs

      Headlines

      Tue, 18 Nov 2014

      * Signs exclusive agreement with Illumina to launch a next-generation sequencing (NGS) epidemiology solution for service labs

    3. Tuttle Tactical Management Weekly Market Notes

      Headlines

      Wed, 5 Nov 2014

      Illumina ILMN reported second-quarter results Tuesday ..... well ahead of our current forecast. Illumina 's instrument revenue was particularly ..... experiments. The more instrument sales Illumina generates in its early years, the more

    4. Market Penetration of Illumina ’s Genome Sequencing Technology Supports Impressive Growth Stride

      Commentary

      Tue, 21 Oct 2014

      expect a minor increase to our fair value estimate for Illumina as the firm's impressive pace of 35% revenue and ..... clinical markets will remain strong tailwinds for Illumina . Illumina ’s ability to drive innovation, regulatory approvals

    5. A Shift in Health-Care M&A Activity

      Headlines

      Sat, 23 Aug 2014

      eventually, we believe it could be a long-term positive for ICON by driving greater outsourcing. Waterhouse : I think Illumina ILMN is an interesting company. We think llumina is currently monopolizing the genome sequencing space. This industry

    6. Illumina ’s Growth and Margin Expansion Momentum Remain Impressive

      Commentary

      Thu, 24 Jul 2014

      Illumina posted impressive second-quarter results that ..... estimate. We think plenty of tailwinds remain for Illumina over the coming years as the genome sequencing market continues to expand, Illumina takes market share, and upcoming regulatory

    7. Qiagen Still Faces Pressure From U.S. HPV Market, Expects More Sequencing Delays

      Commentary

      Thu, 8 May 2014

      the market in mid- to late 2015, considerably behind our own estimate and management's previous expectations. We think Illumina 's recent advances in the sequencing market combined with Qiagen's further delays will make it harder for the company to

    8. Illumina shares up on higher sales of gene-sequencing products

      Headlines

      Tue, 22 Apr 2014

      (Reuters) - Life-science tool maker Illumina Inc reported a better-than-expected jump in quarterly revenue, helped by strong sales of its gene-sequencing products.

    9. New Product Launches Should Support Illumina ’s Strong Growth Trajectory

      Commentary

      Wed, 29 Jan 2014

      Illumina ’s fourth-quarter results came in mostly ..... investor day. As we previously stated, Illumina ’s current growth has exceeded our expectations ..... projections. We also plan to further reevaluate Illumina ’s longer-term opportunity in the genome

    10. From Barron's January 27, 2014

      Commentary

      Sat, 25 Jan 2014

      Lower borrowing costs mean that the buying companies see their added earnings more quickly. Possible future targets: MLM, ILMN and DSW. QUOTE: "I think this company is one of the great no-brainers of all time." Carl Icahn commenting on raising his

    « Prev12345Next »
    Content Partners